VIDEO: Novel VEGF inhibitor under development for wet AMD
Click Here to Manage Email Alerts
ROME — In this Healio Video Perspective from the FLORetina-ICOOR meeting, Angelo Maria Minnella, MD, speaks about sozinibercept, a VEGF-C/D inhibitor under development for the treatment of wet age-related macular degeneration.
Used in association with the classic VEGF-A antagonists, this new drug could provide complete protection against VEGF, enhancing the outcomes of treatment.
The phase 3 ShORe and COAST trials are currently ongoing with the aim of demonstrating the superiority of sozinibercept (Opthea) in combination with ranibizumab or aflibercept as compared with ranibizumab or aflibercept alone.
“This is a new drug that potentially could fill a gap in our standard practice in wet age-related macular degeneration in combination with the daily practice drugs,” Minnella said.
Collapse
Minnella AM. Update on sozinibercept: A new “trap” inhibitor of VEGF C and D under development for the treatment of nAMD. Presented at: FLORetina-ICOOR; Nov. 30-Dec. 3, 2023; Rome.
Click Here to Manage Email Alerts